MIMEDX GROUP INC (MDXG)
Sector: Health Care
2026 Annual Meeting Analysis
MIMEDX GROUP INC · Meeting: June 10, 2026
Directors FOR
2
Directors AGAINST
5
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Mr. Capper has served as CEO and director since January 2023 (approximately 3 years), and during his tenure MDXG's 3-year stock return of -15.7% trails the company-disclosed peer group median of +12.5% by 28.2 percentage points — well above the 20-point threshold that triggers a no vote for directors with negative absolute returns; the 5-year check is not applicable as a mitigant because his tenure began in 2023 and does not cover a full 5-year window that pre-dates the underperformance.
Mr. Bierman has served on the board since June 2019 (approximately 6 years), giving him full overlap with the 3-year underperformance period; MDXG's 3-year return of -15.7% lags the peer group median of +12.5% by 28.2 percentage points, exceeding the 20-point trigger for directors with negative absolute 3-year returns; turning to the 5-year mitigant, the 5-year return of -68.2% versus peer 5-year median of -67.7% shows only a 0.5-point gap, which does not exceed the 20-point threshold, so the 5-year check actually PASSES (gap is below the threshold), meaning underperformance appears concentrated in the recent 3-year window rather than sustained — downgrade from AGAINST to FOR per policy.
Mr. Hawkins has served since July 2020 (approximately 5 years), with meaningful overlap with the 3-year underperformance window; MDXG's 3-year return of -15.7% trails peer median by 28.2 percentage points, triggering the no-vote threshold; applying the 5-year mitigant, the 5-year gap of only -0.5 percentage points versus peers does not exceed the 20-point threshold, so 5-year performance is adequate — per policy, downgrade from AGAINST to FOR, as the 3-year underperformance appears to be a recent development against a longer track record of adequate relative performance.
Mr. Newton has served since June 2019 (approximately 6 years) and has full overlap with the 3-year underperformance period; the 28.2-point lag versus the peer group median exceeds the 20-point trigger; applying the 5-year mitigant, the 5-year gap of -0.5 percentage points does not exceed the 20-point threshold, so the longer record is adequate — per policy, downgrade from AGAINST to FOR.
Mr. Sutter has served since July 2020 (approximately 5 years), with full overlap with the 3-year underperformance period; MDXG's 3-year return trails peer median by 28.2 points, exceeding the 20-point trigger; applying the 5-year mitigant, the 5-year gap of -0.5 percentage points does not exceed the 20-point threshold, so long-term relative performance is adequate — per policy, downgrade from AGAINST to FOR.
For Analysis
Ms. Olson joined the board in March 2024, which is within the 24-month new-director exemption window, so she is exempt from the TSR underperformance trigger and receives a FOR vote; she also brings relevant healthcare industry and commercial executive experience.
Ms. Puhy joined the board in March 2024, which is within the 24-month new-director exemption window, so she is exempt from the TSR underperformance trigger; she brings strong financial expertise (former CFO/COO of Dana-Farber Cancer Institute) and serves as an audit committee financial expert, satisfying key governance criteria.
The 3-year TSR underperformance trigger fires for all directors with tenure exceeding 24 months: MDXG's 3-year return of -15.7% lags the company-disclosed peer group median of +12.5% by 28.2 percentage points, exceeding the 20-point threshold for companies with negative absolute 3-year returns. However, the 5-year mitigant applies to all long-tenured directors except CEO Capper (whose tenure began in 2023 and does not span a meaningful pre-underperformance period): the 5-year peer gap of only -0.5 percentage points is well below the 20-point threshold, indicating the underperformance is a recent phenomenon rather than a sustained pattern. As a result, under the 5-year mitigant, Bierman, Hawkins, Newton, and Sutter are downgraded from AGAINST to FOR. CEO Capper remains AGAINST because his full tenure as both executive and director coincides with the underperformance period and the 5-year mitigant is not available for his shorter tenure. Olson and Puhy joined within the past 24 months and are exempt from the TSR trigger.
Say on Pay
✗ AGAINSTCEO
Joseph H. Capper
Total Comp
$7,182,208
Prior Support
93.2%%
The pay-for-performance alignment check fails: the CEO received total compensation of $7,182,208 in 2025 — including above-benchmark incentive payouts at 115% of target after the Committee exercised discretion to raise bonuses above 100% — while the stock fell 55.4% during the year and MDXG's 3-year return of -15.7% trailed the company-disclosed peer median of +12.5% by 28.2 percentage points, well above the 20-point misalignment threshold. Although the Committee acknowledged the disconnect between maximum-payout performance metrics and share price and reduced the cash bonus from 135% to 115%, paying above-benchmark incentive compensation while shareholders experienced significant losses represents a failure of pay-for-performance alignment under our policy. The prior year's 93.2% approval is a positive signal on governance process, but the structural problem — above-benchmark variable pay awarded during a period of sharp stock underperformance — is the determining factor in a no vote.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
N/A
Audit Fees
$1,733,500
Non-Audit Fees
$1,875
Non-audit fees of $1,875 represent less than 1% of audit fees of $1,733,500, far below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire per policy; Deloitte is a Big 4 firm appropriate for MDXG's size and complexity; all fees were pre-approved by the Audit Committee.
Overall Assessment
The 2026 MiMedx annual meeting presents three proposals; we vote AGAINST Say on Pay due to above-target incentive payouts during a period of severe stock underperformance (-55% in 2025, -15.7% over 3 years versus a peer median of +12.5%), and AGAINST CEO Capper's re-election as a director because his full tenure coincides with the 3-year underperformance period without the benefit of a mitigating longer track record. All other director nominees receive FOR votes (long-tenured directors pass the 5-year mitigant test; newer directors are within the 24-month exemption window), and Deloitte's re-appointment is supported given a negligible non-audit fee ratio and no other disqualifying factors.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing